Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer's disease.

Key facts

Study ID

NCT02600130

Run by

Longeveron Inc.

People needed

33

Starts

2016-10-10

Expected to finish

2021-09-01

Last updated by the study team

2021-12-14

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Brain Matters Research — Delray Beach, Florida, United States
• University of Miami Miller School of Medicine — Miami, Florida, United States
• Miami Jewish Health — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.